STOCK TITAN

Ocean Biomedical, Inc. - OCEA STOCK NEWS

Welcome to our dedicated page for Ocean Biomedical news (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.

Ocean Biomedical, Inc. (symbol: OCEA) is a pioneering biopharmaceutical company focused on transforming basic research into groundbreaking clinical treatments. The company excels in partnering with inventor-scientists and premier research institutes to bridge the critical gap between laboratory discoveries and clinical applications. This unique approach aims to expedite the development of new medicines, ensuring that groundbreaking treatments reach the patients who need them most.

Ocean Biomedical is at the forefront of medical innovation, dedicating its resources to crucial areas of unmet medical needs. The company's operations span several key areas, including chronic hepatitis B and other serious diseases, where there is a significant demand for advanced therapeutic solutions.

In recent times, Ocean Biomedical has made notable strides in its projects and collaborations, enhancing its portfolio of potential treatments. For instance, the ongoing development of VRON-0200, in collaboration with Virion Therapeutics, showcases the company’s commitment to addressing chronic hepatitis B. Such initiatives not only enhance the company's market position but also underline its commitment to improving global health outcomes.

Financially, Ocean Biomedical has maintained a stable condition, driven by strategic partnerships and thoughtful financial planning. The company actively engages with investors and stakeholders through regular updates and transparent communication. For more information, the investor relations team can be reached at connect@oceanbiomedical.com.

Ocean Biomedical's significance in the biopharmaceutical industry cannot be overstated. By focusing on the translational process from research to clinical development, the company plays a vital role in the healthcare ecosystem. This holistic and patient-centric approach ensures that new medical discoveries are not just theoretical but are translated into viable treatments that can dramatically improve patient quality of life.

For more updates on Ocean Biomedical's latest news, projects, and collaborations, visit their official website at www.oceanbiomedical.com.

Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced new findings in the peer-reviewed journal Immunity detailing the role of CHI3L1 in the growth of triple negative breast cancer. The research demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from killing the tumor. Ocean's anti-CHI3L1 antibody shows potential in reversing this process and suppressing breast cancer tumor growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) received a notice from Nasdaq stating non-compliance with filing its quarterly report on Form 10-Q for the period ended September 30, 2023. The company is delayed in filing due to an interpretation of SEC accounting guidance for certain Forward Purchase Agreements. Ocean Biomedical has to submit a plan by January 22, 2024, to regain compliance and file the delinquent Form 10-Q by May 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced that its joint venture partner, Virion Therapeutics, presented compelling preclinical oncology data at SITC 2023, demonstrating complete tumor clearance and a 10-fold increase in T cell responses. Virion is also enrolling their Phase 1b clinical trial for chronic hepatitis B virus with VRON-0200, targeting a $6.5B+ market opportunity by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.36%
Tags
none
Rhea-AI Summary
Ocean Biomedical's joint venture partner, Virion Therapeutics, has dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy for chronic Hepatitis B virus (HBV) infection. VRON-0200, a first-in-class treatment, aims to enhance and broaden a patient's immune response to overcome immune exhaustion. Initial clinical data is expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Summary
Virion Therapeutics and Ocean Biomedical have announced the dosing of the first patients in the Phase 1b clinical trial of their investigational immunotherapy VRON-0200 for chronic Hepatitis B virus (HBV) infection. The treatment aims to enhance and broaden a patient's immune response to overcome immune exhaustion. Initial clinical data is expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) announced that its Chief Scientist, Jonathan Kurtis MD, PhD, has received the Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates. The program aims to address the growing resistance to current malaria medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
Rhea-AI Summary
Ocean Biomedical announces enrollment of patients in Phase 1b study for Hepatitis B treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Ocean Biomedical, Inc. announces a Side Letter agreement with Polar Multi-Strategy Master Fund.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
Rhea-AI Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) has entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LLC, for a proposed debt facility of up to $10 million. The promissory notes will have a conversion price of $10.34 per share and Poseidon will receive warrant coverage with an initial exercise price of $11.50 per share. The financing transaction is subject to further negotiation and the consent of the current senior lender. No assurance of a definitive agreement or consummation of the transaction. The securities have not been registered under the Securities Act of 1933.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.6%
Tags
none

FAQ

What is the current stock price of Ocean Biomedical (OCEA)?

The current stock price of Ocean Biomedical (OCEA) is $0.69 as of November 20, 2024.

What is the market cap of Ocean Biomedical (OCEA)?

The market cap of Ocean Biomedical (OCEA) is approximately 25.1M.

What does Ocean Biomedical, Inc. do?

Ocean Biomedical, Inc. is a biopharmaceutical company dedicated to bridging the gap between basic research and clinical development to bring new medicines to patients.

What is the stock symbol for Ocean Biomedical, Inc.?

The stock symbol for Ocean Biomedical, Inc. is OCEA.

What are some recent projects of Ocean Biomedical?

Ocean Biomedical is actively developing VRON-0200 for chronic hepatitis B in collaboration with Virion Therapeutics and several other innovative clinical treatments.

How does Ocean Biomedical maintain its financial health?

The company maintains financial stability through strategic partnerships, thorough financial planning, and transparent communication with investors.

Who are the key partners of Ocean Biomedical?

Ocean Biomedical collaborates with leading inventor-scientists, research institutes, and organizations like Virion Therapeutics.

How can investors contact Ocean Biomedical?

Investors can contact Ocean Biomedical through their investor relations team at connect@oceanbiomedical.com.

What diseases does Ocean Biomedical focus on?

Ocean Biomedical focuses on diseases with significant unmet needs, including chronic hepatitis B and other serious medical conditions.

Where can I find more information about Ocean Biomedical's projects?

More information about Ocean Biomedical's projects can be found on their official website at www.oceanbiomedical.com.

What is Ocean Biomedical's approach to clinical development?

Ocean Biomedical partners with leading scientists and research institutes to translate basic research into clinical treatments, aiming to deliver innovative medicines to patients.

Who is the Communications Director of Ocean Biomedical?

Kevin Kertscher serves as the Communications Director of Ocean Biomedical.

Ocean Biomedical, Inc.

Nasdaq:OCEA

OCEA Rankings

OCEA Stock Data

25.09M
9.71M
71.99%
10.58%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK